Advancing treatments for rare childhood brain tumours: New models, new hope?
Followed by an informal chat over lunch. Register here for lunch with Sigourney: https://forms.office.com/Pages/ResponsePage.aspx?id=G96VzPWXk0-0uv5ouFLPkegV2gJFGQhEre5d0PC4DrJURVI3MjhINjNKTzNYTko3MVFER0lXME5POS4u
Sigourney is a postdoctoral associate at the Cancer Research UK Cambridge Institute at the University of Cambridge. Her recently completed PhD focussed on developing novel models and therapeutics for a rare paediatric brain tumour. She earned her BSc in Human Physiology from the University of Leeds and then went on to work for both Pfizer and AstraZeneca in both neuroscience and oncology. Alongside her science career, Sigourney is also the CEO of Black in Cancer, an organisation that aims to empower and encourage future Black Cancer leaders whilst reducing cancer disparities through education and advocacy. She was also recently named as a Forbes 30 under 30 honouree for her work.

Co-Founder and CEO of ‘Black in Cancer’
PostDoctoral Researcher at CRUK Cambridge Institute
Forbes 30 under 30 awardee in ‘Science & Healthcare’
Date: 28 October 2024, 12:30 (Monday, 3rd week, Michaelmas 2024)
Venue: Wellcome Trust Centre for Human Genetics, Headington OX3 7BN
Venue Details: Seminar Room A
Speaker: Dr. Sigourney Bonner
Organising department: Nuffield Department of Clinical Medicine
Organisers: Christina Heroven (CAMS Oxford Institute), Mimie Szyk (CAMS Oxford Institute), Robert Beagrie (University of Oxford)
Booking required?: Not required
Audience: Members of the University only
Editor: Mimie Szyk